| Model Number |
FR995-25 |
| Medical Device Problem Code |
Perivalvular Leak (1457)
|
| Health Effect - Clinical Code |
Valvular Insufficiency/ Regurgitation (4449)
|
| Date of Event |
12/03/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that 12 years and 11 months post implant of this 25mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was reported as severe paravalvular leak (pvl) regurgitation.No intervention or adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b.2: outcome attributed to adverse event b.5: event description e.1: initial reporter.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that reported subsequently, 2 days later, a different manufacturers transcatheter valve was implanted valve-in-valve.No additional adverse patient effects were reported.
|
| |
|
Search Alerts/Recalls
|